# Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status

> **NCT00689221** · PHASE3 · COMPLETED · sponsor: **EMD Serono** · enrollment: 545 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Cilengitide
- **DRUG:** Temozolomide
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT00689221
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2012-11
- **Final completion:** 2013-08
- **Target enrollment:** 545 (ACTUAL)
- **Last updated:** 2014-11-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00689221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00689221, "Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00689221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*